Autek China Inc

Autek China Inc maintains a strong liquidity position, with a current ratio of 5.77, indicating the company can easily cover its short-term liabilities with its current assets. The company's liquidity_fpt score is high, supported by a free cash flow of 327.8 million CNY and a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.06 suggests a conservative capital structure, with minimal leverage relative to equity. In terms of profitability, Autek China Inc reports a return on equity (ROE) of 9.76% and a return on assets (ROA) of 7.66%, both of which are strong indicators of efficient capital use and asset management. These figures are well above the industry median for medical equipment and supplies firms, suggesting the company is outperforming its peers in generating returns. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic shifts and regulatory changes, particularly in the Chinese healthcare market. The absence of segment-specific revenue breakdowns limits visibility into the company's operational resilience and growth drivers. Autek China Inc is experiencing a positive growth trajectory, with a revenue of 1.86 billion CNY in the latest reporting period. While no forward-looking revenue guidance is provided, the company's operating cash flow of 730.1 million CNY and free cash flow of 327.8 million CNY suggest strong cash generation capabilities. The capital expenditure of -120.7 million CNY indicates a reduction in investment, which may signal a shift in strategic focus or a response to market conditions. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The risk assessment highlights a key flag: net cash is negative after subtracting total debt, which could impact the company's ability to fund operations without external financing. However, the dilution risk is low, with no near-term pressure from share issuance or convertible instruments. Recent events include analyst estimates that suggest a mixed outlook, with a mean price target of 16.28 CNY and a median of 17.75 CNY. The mean recommendation of 2.83 (on a 1-5 scale) indicates a cautious outlook, with no strong buy ratings and three hold ratings. These signals suggest that while the company is not seen as a high-growth opportunity, it is considered a stable investment.